Loading...
Loading...
Hi-Tech Pharmacal Co., Inc.
HITK announced today that its
Health Care Products Over The Counter (OTC) division received a Warning
Letter from Food and Drug Administration (FDA) dated July 15, 2013. The
Warning Letter is related to certain statements that appear on labeling
of Diabeti-Derm® Antifungal Cream, Zostrix® Diabetic Foot Pain Relief
Cream and Zostrix® Diabetic Joint & Arthritis Pain Relief Cream. HCP
intends to fully comply with the requirements set forth in the Warning
Letter. The products that are the subject of the Warning Letter had Net
Sales of approximately $1.1 million in fiscal 2013.
Hi-Tech is a specialty pharmaceutical company developing, manufacturing
and marketing generic and branded prescription and OTC products. The
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in